The company began publicly trading on the Nasdaq on Oct. 20 under the ticker “PRIME.”
Prime Medicine’s flagship gene-editing product has the potential to repair 90 percent of disease-causing genetic mutations, according to an Oct. 24 Prime news release provided to Becker’s.
J.P. Morgan, Goldman Sachs, Morgan Stanley and Jefferies serve as book-running managers for the offering.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
